药物促进骨形成——骨质疏松症治疗新举措

被引:23
作者
沈龙祥
曾炳芳
机构
[1] 上海交通大学附属第六人民医院骨科
关键词
骨质疏松; 特立帕肽; 骨形成;
D O I
暂无
中图分类号
R580 [];
学科分类号
摘要
骨质疏松症是人体骨吸收与骨形成不平衡的结果,抑制骨吸收和促进骨形成均可治疗骨质疏松。特立帕肽是全长甲状旁腺素(PTH)的N末端第1~34个氨基酸片断,其重组形式复泰奥是迄今唯一被美国食品药品监督管理局(FDA)批准用于治疗骨质疏松症的促骨形成药物。众多随机对照试验显示,特立帕肽能升高血清骨形成标志物,增加骨密度,降低骨质疏松性骨折发生风险,其抑制骨吸收的效果优于双膦酸盐。美国推荐特立帕肽治疗高骨折风险的骨质疏松,加拿大则推荐特立帕肽为治疗严重骨质疏松的一线药物。
引用
收藏
页码:135 / 140
页数:6
相关论文
共 21 条
[1]
Use of teriparatide in osteoporotic fracture patients.[J].Cory Collinge;Juan Favela.Injury.2016,
[2]
Teriparatide Versus Alendronate for the Preservation of Bone Mineral Density After Total Hip Arthroplasty – A randomized Controlled Trial.[J].Naomi Kobayashi;Yutaka Inaba;Makoto Uchiyama;Hiroyuki Ike;So Kubota;Tomoyuki Saito.The Journal of Arthroplasty.2016, 1
[3]
Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial [J].
Leder, Benjamin Z. ;
Tsai, Joy N. ;
Uihlein, Alexander V. ;
Wallace, Paul M. ;
Lee, Hang ;
Neer, Robert M. ;
Burnett-Bowie, Sherri-Ann M. .
LANCET, 2015, 386 (9999) :1147-1155
[4]
Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-na?ve or on long-term alendronate therapy.[J].B. Hofstetter;S. Gamsjaeger;F. Varga;H. Dobnig;J. J. Stepan;H. Petto;I. Pavo;K. Klaushofer;E. P. Paschalis.Osteoporosis International.2014, 12
[5]
Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial [J].
Leder, Benjamin Z. ;
Tsai, Joy N. ;
Uihlein, Alexander V. ;
Burnett-Bowie, Sherri-Ann M. ;
Zhu, Yuli ;
Foley, Katelyn ;
Lee, Hang ;
Neer, Robert M. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (05) :1694-1700
[6]
Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: Results from the European Forsteo Observational Study [J].
Rajzbaum, Gerald ;
Grados, Franck ;
Evans, David ;
Liu-Leage, Soyi ;
Petto, Helmut ;
Augendre-Ferrante, Beatrice .
JOINT BONE SPINE, 2014, 81 (01) :69-75
[7]
Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial [J].
Sugimoto, Toshitsugu ;
Shiraki, Masataka ;
Nakano, Tetsuo ;
Kishimoto, Hideaki ;
Ito, Masako ;
Fukunaga, Masao ;
Hagino, Hiroshi ;
Sone, Teruki ;
Kuroda, Tatsuhiko ;
Nakamura, Toshitaka .
CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (03) :195-203
[8]
Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial [J].
Glueer, Claus-C ;
Marin, Fernando ;
Ringe, Johann D. ;
Hawkins, Federico ;
Moericke, Ruediger ;
Papaioannu, Nikolaos ;
Farahmand, Parvis ;
Minisola, Salvatore ;
Martinez, Guillermo ;
Nolla, Joan M. ;
Niedhart, Christopher ;
Guanabens, Nuria ;
Nuti, Ranuccio ;
Martin-Mola, Emilio ;
Thomasius, Friederike ;
Kapetanos, Georgios ;
Pena, Jaime ;
Graeff, Christian ;
Petto, Helmut ;
Sanz, Beatriz ;
Reisinger, Andreas ;
Zysset, Philippe K. .
JOURNAL OF BONE AND MINERAL RESEARCH, 2013, 28 (06) :1355-1368
[9]
Teriparatide Accelerates Lumbar Posterolateral Fusion in Women With Postmenopausal Osteoporosis Prospective Study [J].
Ohtori, Seiji ;
Inoue, Gen ;
Orita, Sumihisa ;
Yamauchi, Kazuyo ;
Eguchi, Yawara ;
Ochiai, Nobuyasu ;
Kishida, Shunji ;
Kuniyoshi, Kazuki ;
Aoki, Yasuchika ;
Nakamura, Junichi ;
Ishikawa, Tetsuhiro ;
Miyagi, Masayuki ;
Kamoda, Hiroto ;
Suzuki, Miyako ;
Kubota, Gou ;
Sakuma, Yoshihiro ;
Oikawa, Yasuhiro ;
Inage, Kazuhide ;
Sainoh, Takeshi ;
Takaso, Masashi ;
Ozawa, Tomoyuki ;
Takahashi, Kazuhisa ;
Toyone, Tomoaki .
SPINE, 2012, 37 (23) :E1464-E1468
[10]
The effects of parathyroid hormone; alendronate; or both in men with osteoporosis..Finkelstein J S; Hayes A; Hunzelman J L; et al;.N Engl J Med.2003,